Related references
Note: Only part of the references are listed.Spontaneous Reactivation of Hepatitis B Virus (HBV) Infection in Patients With Resolved or Occult HBV Infection
Hiroshi Kamitsukasa et al.
JOURNAL OF MEDICAL VIROLOGY (2015)
Ever-advancing chronic myeloid leukemia treatment
Shinya Kimura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up
Shin Fujisawa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases
Michinori Aoe et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Frequent Incidence of Escape Mutants After Successful Hepatitis B Vaccine Response and Stopping of Nucleos(t)ide Analogues in Liver Transplant Recipients
Masatoshi Ishigami et al.
LIVER TRANSPLANTATION (2014)
Management of patients with hepatitis B who require immunosuppressive therapy
Jessica P. Hwang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues
M. Woelfl et al.
BONE MARROW TRANSPLANTATION (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2013)
Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor
Guan-Min Lai et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
Makoto Oketani et al.
HEPATOLOGY RESEARCH (2012)
Reactivation of Overt and Occult Hepatitis B Infection in Various Immunosuppressive Settings
Nicola Coppola et al.
JOURNAL OF MEDICAL VIROLOGY (2011)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A. Kreutzman et al.
LEUKEMIA (2011)
Molecular genesis of drug-resistant and vaccine-escape HBV mutants
Stephen A. Locarnini et al.
ANTIVIRAL THERAPY (2010)
Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier
N. Fukushima et al.
ANNALS OF ONCOLOGY (2009)
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2009)
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Dong Hwan Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review
Byung Woog Kang et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan
Takeji Umemura et al.
CLINICAL INFECTIOUS DISEASES (2008)
Hepatitis B virus escape mutants induced by antiviral therapy
Julie Sheldon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
J. Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment
K Ikeda et al.
LEUKEMIA & LYMPHOMA (2006)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
K Cwynarski et al.
LEUKEMIA (2004)
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy
TH Westhoff et al.
BLOOD (2003)
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP:: a diagnostic and therapeutic challenge
C Skrabs et al.
LEUKEMIA (2002)
Share Paper
